Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Societal CDMO, Inc. (REPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/14/2022 |
8-K/A
| Financial Statements and Exhibits Interactive Data|
Docs:
|
"Recro Pharma, Inc. Unaudited Pro Forma Combined Statements of Operations Nine Months Ended September 30, 2021 Recro Pre-acquisition IriSys Nine months ended September 30, 2021 Six months ended June 30, 2021 July 1 to August 12, 2021 Pro forma adjustments Pro forma combined Revenue $ 53,057 $ 6,844 $ 1,142 $ — $ 61,043 Operating expenses: Cost of sales 39,831 3,529 810 470 44,640 Selling, general and administrative 13,076 3,088 618 15,571 Amortization of intangible assets 835 - - 650 1,485 Total operating expenses 53,742 6,617 1,428 61,696 Operating income 227 91 Interest expense Gain on extinguishment of debt 3,352 866 - - 4,218 Net income $ $ 1,006 $ $ $ Loss per share: Basic $ $ Diluted Weighted average shares outstanding Basic 40,137,069 7,667,075 47,804,144 Diluted 40,137,069 7,66..." |
|
| 09/10/2021 |
8-K/A
| Quarterly results |
| 03/06/2019 |
8-K/A
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 04/29/2016 |
8-K/A
| Financial Statements and Exhibits |
|
|